300 Guangzhou Road
Nanjing, 210029
China
Nanjing Medical University
SARS-CoV-2, heterologous immunisation, recombinant adenovirus type-5-vectored COVID-19 vaccine, protein-subunit-based COVID-19 vaccine, clinical trial